This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donfrancesco, A. Articles by Helson, L. Search for Related Content PubMed PubMed Citation Articles by Donfrancesco, A. Articles by Helson, L.

Effects of a Single Course of Deferoxamine in Neuroblastoma Patients¹

Pediatric Oncology Service, Ospedale Bambino Gesu' [A. D., G. D., D. P.] and Department of Pediatrics, University "La Sapienza" [C. D., M. A. C.], Rome, Italy, and Department of Pediatrics, New York Medical College, New York, New York [L. H.]

A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed. Within 2 days of completion of treatment responses were observed in 7 of 9 patients and there was no drug toxicity. These responses were a decrease in bone marrow infiltration and, in one patient, a measurable reduction in her tumor mass. We conclude that deferoxamine given as an 8-h i.v. infusion daily for 5 days at 150 mg/kg/day has antitumor activity.

¹ This work was supported by the Neuroblastoma Foundation of New York.

² To whom requests for reprints should be addressed, at Servizio di Oncologia, Ospedale Bambino Gesu', Piazza S. Onofrio, 4, 00165 Rome, Italy.

Received 9/11/89. Revised 4/16/90.

This article has been cited by other articles:

				D. Fu and D. R. Richardson Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion Blood, July 15, 2007; 110(2): 752 - 761. [Abstract] [Full Text] [PDF]

				Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond Clin. Cancer Res., December 1, 2006; 12(23): 6876 - 6883. [Abstract] [Full Text] [PDF]

				D. T. Jones, I. S. Trowbridge, and A. L. Harris Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res., March 1, 2006; 66(5): 2749 - 2756. [Abstract] [Full Text] [PDF]

				D. S. Kalinowski and D. R. Richardson The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer Pharmacol. Rev., December 1, 2005; 57(4): 547 - 583. [Abstract] [Full Text] [PDF]

				T. B. Chaston, R. N. Watts, J. Yuan, and D. R. Richardson Potent Antitumor Activity of Novel Iron Chelators Derived from Di-2-Pyridylketone Isonicotinoyl Hydrazone Involves Fenton-Derived Free Radical Generation Clin. Cancer Res., November 1, 2004; 10(21): 7365 - 7374. [Abstract] [Full Text] [PDF]

				N. T.V. Le and D. R. Richardson Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation Blood, November 1, 2004; 104(9): 2967 - 2975. [Abstract] [Full Text] [PDF]

				J. Yuan, D. B. Lovejoy, and D. R. Richardson Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood, September 1, 2004; 104(5): 1450 - 1458. [Abstract] [Full Text] [PDF]

				N. T.V. Le and D. R. Richardson Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1, but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation Carcinogenesis, June 1, 2003; 24(6): 1045 - 1058. [Abstract] [Full Text] [PDF]

				B. De Bernardi, B. Nicolas, L. Boni, P. Indolfi, M. Carli, L. Cordero di Montezemolo, A. Donfrancesco, A. Pession, M. Provenzi, A. di Cataldo, et al. Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma J. Clin. Oncol., April 15, 2003; 21(8): 1592 - 1601. [Abstract] [Full Text] [PDF]

				T. B. Chaston, D. B. Lovejoy, R. N. Watts, and D. R. Richardson Examination of the Antiproliferative Activity of Iron Chelators: Multiple Cellular Targets and the Different Mechanism of Action of Triapine Compared with Desferrioxamine and the Potent Pyridoxal Isonicotinoyl Hydrazone Analogue 311 Clin. Cancer Res., January 1, 2003; 9(1): 402 - 414. [Abstract] [Full Text] [PDF]

				D. B. Lovejoy and D. R. Richardson Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells Blood, June 28, 2002; 100(2): 666 - 676. [Abstract] [Full Text] [PDF]

				K. J. Thompson, M. G. Fried, Z. Ye, P. Boyer, and J. R. Connor Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei J. Cell Sci., May 15, 2002; 115(10): 2165 - 2177. [Abstract] [Full Text] [PDF]

				D. A. Green, W. E. Antholine, S. J. Wong, D. R. Richardson, and C. R. Chitambar Inhibition of Malignant Cell Growth by 311, a Novel Iron Chelator of the Pyridoxal Isonicotinoyl Hydrazone Class: Effect on the R2 subunit of Ribonucleotide Reductase Clin. Cancer Res., November 1, 2001; 7(11): 3574 - 3579. [Abstract] [Full Text] [PDF]

				R. D. Abeysinghe, B. T. Greene, R. Haynes, M. C. Willingham, J. Turner, R. P. Planalp, M.W. Brechbiel, F. M. Torti, and S. V. Torti p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator Carcinogenesis, October 1, 2001; 22(10): 1607 - 1614. [Abstract] [Full Text] [PDF]

				J. Gao and D. R. Richardson The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression Blood, August 1, 2001; 98(3): 842 - 850. [Abstract] [Full Text] [PDF]

				G. Darnell and D.R. Richardson The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents III: The Effect of the Ligands on Molecular Targets Involved in Proliferation Blood, July 15, 1999; 94(2): 781 - 792. [Abstract] [Full Text] [PDF]

				D.R. Richardson and K. Milnes The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents II: The Mechanism of Action of Ligands Derived From Salicylaldehyde Benzoyl Hydrazone and 2-Hydroxy-1-Naphthylaldehyde Benzoyl Hydrazone Blood, April 15, 1997; 89(8): 3025 - 3038. [Abstract] [Full Text] [PDF]